Aim: This study aims to compare efficacy and safety between mesotherapy (intralesional injection) and 5% topical minoxidil solution in male androgenic alopecia (AGA) by dermoscopic evaluation. of locks shaft diameter between pre- and post-treatment in mesotherapy group compared to minoxidil group. The rest of parameters failed to show any significant difference within the group in mesotherapy and minoxidil. Conclusion: In our study, we observed a significant increase in the variation of hair shaft diameter between pre- and post-treatment in Group A compared to B. Other dermoscopic, trichoscan, and subjective measurement tool failed to show Fargesin significant difference between two groups. Our observation suggests that there is no significant improvement of mesotherapy in male AGA over minoxidil. = 25) and minoxidil Group B (= 24). We excluded males who were on any allopathic treatment for hair loss within last 6 months, having other scalp dermatoses, prior major illness or hospitalization, thyroid disease, systemic illness, anemia, taking psychiatric medications, and those refusing for consent for enrolling into the study and long follow-up. Detailed clinical record was prepared on a predesigned pro forma, and all the patients were subjected to detailed history. Nature of the disease, various treatment options, and prognosis of each treatment modality were explained to the patient before enrolling them. Routine investigations such as complete blood count, renal and liver function test, random blood sugar, viral markers such as HIV, hepatitis B surface antigen, hepatitis C, and thyroid function test were carried out before commencing the treatment to rule out infection, thyroid disorder, anemia, and systemic illness. Therapy group Mesotherapy Patients were enrolled for mesotherapy group after performing intradermal allergy testing with mesosolution. After applying topical anesthesia, intradermal injections of mesosolution were given combined with microneedling. Any adverse events were noted during the procedure, and if no complications appeared, patient was allowed to go home. Mesohair solution contained 56 ingredients including 24 amino acids, 13 vitamins, 4 coenzymes, 4 nucleic acids, 5 minerals, and 2 reducing agents. The active ingredient was decapeptide 4, acetyl decapeptide, and copper tripeptide [Figure 1]. Open in a separate window Figure 1 Derma roller Fargesin and mesosolution Rabbit Polyclonal to Smad1 (phospho-Ser465) Follow-up This procedure was repeated weekly for 1 month followed by fortnightly for 2nd month and then every monthly for 2 months. Hence, in total, eight sessions were carried out. Postoperative advice Patients were advised not to wash, comb, or itch their scalp for 3 days after the procedure. They were asked to restrain from heavy exercise, apply oil or dye, and going out bareheaded in pollution for 3 days. Minoxidil Patient Fargesin under minoxidil Group B was prescribed application of 2C3 ml of 5% minoxidil solution twice daily on the bald areas of scalp. They were explained the side effects such as initial hair Fargesin loss for 1C2 months, headache, redness, and irritation. They were also reassured about the lag period of about 2C3 months for the improvement. Evaluation method All Fargesin the enrolled males were evaluated before starting therapy and then monthly till 4 months. Gross photographs were taken under adequate illumination, identical settings, lighting, and position. Measuring tape was used to determine three fixed point on the scalp for future dermoscopic evaluation. Landmarks for each frontal region were the intersecting point between lines passing through ipsilateral tragus and lateral point of eyebrows and the intersection of two imaginary line crossing both the ears and glabella for vertex region. A Heine Delta 20 Plus videodermoscope (Germany) with polarized light that is attached with digital camera.
Aim: This study aims to compare efficacy and safety between mesotherapy (intralesional injection) and 5% topical minoxidil solution in male androgenic alopecia (AGA) by dermoscopic evaluation
Posted in Steroid Hormone Receptors
Categories
- 34
- 5- Receptors
- A2A Receptors
- ACE
- Acetylcholinesterase
- Adenosine Deaminase
- Adenylyl Cyclase
- Adrenergic ??2 Receptors
- Alpha2 Adrenergic Receptors
- Annexin
- Antibiotics
- ATPase
- AXOR12 Receptor
- Ca2+ Ionophore
- Cannabinoid
- Cannabinoid (GPR55) Receptors
- CB2 Receptors
- CCK Receptors
- Cell Metabolism
- Cell Signaling
- Cholecystokinin2 Receptors
- CK1
- Corticotropin-Releasing Factor1 Receptors
- DHCR
- DMTases
- DNA Ligases
- DNA Methyltransferases
- Dopamine D1 Receptors
- Dopamine D3 Receptors
- Dopamine D4 Receptors
- Endothelin Receptors
- EP1-4 Receptors
- Epigenetics
- Exocytosis & Endocytosis
- Fatty Acid Synthase
- Flt Receptors
- GABAB Receptors
- GIP Receptor
- Glutamate (Kainate) Receptors
- Glutamate (Metabotropic) Group III Receptors
- Glutamate (NMDA) Receptors
- Glutamate Carboxypeptidase II
- Glycogen Phosphorylase
- Glycosyltransferase
- GnRH Receptors
- Heat Shock Protein 90
- hERG Channels
- Hormone-sensitive Lipase
- IKK
- Imidazoline Receptors
- IMPase
- Inositol Phosphatases
- Kisspeptin Receptor
- LTA4 Hydrolase
- M1 Receptors
- Matrixins
- Melastatin Receptors
- mGlu Group III Receptors
- mGlu5 Receptors
- Monoamine Oxidase
- Motilin Receptor
- My Blog
- Neutrophil Elastase
- Nicotinic (??4??2) Receptors
- NKCC Cotransporter
- NMU Receptors
- Nociceptin Receptors
- Non-Selective
- Non-selective 5-HT
- OP3 Receptors
- Opioid, ??-
- Orexin2 Receptors
- Other
- Other Oxygenases/Oxidases
- Other Transcription Factors
- p38 MAPK
- p53
- p56lck
- PAF Receptors
- PDPK1
- PKC
- PLA
- PPAR
- PPAR??
- Proteasome
- PTH Receptors
- Ras
- RNA Polymerase
- Serotonin (5-HT2B) Receptors
- Serotonin Transporters
- Sigma2 Receptors
- Sodium Channels
- Steroid Hormone Receptors
- Tachykinin NK1 Receptors
- Tachykinin NK2 Receptors
- Tachykinin, Non-Selective
- Telomerase
- Thyrotropin-Releasing Hormone Receptors
- Topoisomerase
- trpp
- Uncategorized
- USP
Recent Posts
- 2012) using the Phenotypic Characteristic Search for human strains with markers for resistance to Adamantane, Oseltamivir, or both drugs
- Tissue were homogenized into single-cell suspensions and put through red bloodstream cell lysis
- A phase I/II study investigated the safety and efficacy of concurrent local palliative RT and durvalumab (PD-L1 inhibitor) in 10 patients with unresectable or metastatic advanced solid tumors [136]
- We believe that this hypothesis-generating study could open new avenues for exploring oxidative stress as a potential pathogenetic and, hypothetically, therapeutic target for mitigating CLL strong class=”kwd-title” Keywords: Leukemia, Lymphocytic, Gilbert’s, Syndrome Gilbert’s syndrome (GS) is the most common inherited disorder of bilirubin glucuronidation
- Such costs aren’t simple for tertiary-care hospitals in growing countries sometimes, since these already are powered by minimal budget which switches into provision of fundamental medical services mostly, laboratory, radiology, pharmacy services, and bed space
Tags
a 67 kDa type I transmembrane glycoprotein present on myeloid progenitors
and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes
Apoptosis
bladder
brain
breast
cell cycle progression
cervix
CSP-B
Cyproterone acetate
EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck
EM9
endometrium
erythrocytes
F3
Goat polyclonal to IgG H+L)
Goat polyclonal to IgG H+L)Biotin)
GRK4
GSK1904529A
Igf1
Mapkap1
monocytes andgranulocytes. CD33 is absent on lymphocytes
Mouse monoclonal to CD33.CT65 reacts with CD33 andtigen
Palomid 529
platelets
PTK) or serine/threonine
Rabbit Polyclonal to ARNT.
Rabbit polyclonal to BMPR2
Rabbit Polyclonal to CCBP2.
Rabbit Polyclonal to EDG4
Rabbit polyclonal to EIF4E.
Rabbit polyclonal to IL11RA
Rabbit polyclonal to LRRIQ3
Rabbit Polyclonal to MCM3 phospho-Thr722)
Rabbit Polyclonal to RBM34
SB 216763
SKI-606
SNX-5422
STK) kinase catalytic domains. Epidermal Growth factor receptor
stomach
stomach and in squamous cell carcinoma.
TNFSF8
TSHR
VEGFA
vulva